Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels

NCT05865535 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05865535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05865535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 13, 2023
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cachexia